Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML
2018; Elsevier BV; Volume: 132; Issue: 6 Linguagem: Inglês
10.1182/blood-2018-01-821629
ISSN1528-0020
AutoresJorge E. Cortés, Martin S. Tallman, Gary J. Schiller, Denise Trone, Guy Gammon, Stuart L. Goldberg, Alexander E. Perl, Jean-Pierre Marie, Giovanni Martinelli, Hagop M. Kantarjian, Mark J. Levis,
Tópico(s)Chronic Lymphocytic Leukemia Research
ResumoKey Points Quizartinib at 60 mg/day (vs 30 mg/day) was associated with higher overall response, survival, and bridge to transplant. The benefit-risk profile of quizartinib in relapsed or refractory FLT3-ITD–mutated AML warrants further evaluation of 60-mg once-daily dose.
Referência(s)